Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Age De-escalation Dose-escalation Randomised, Double-blind, Controlled Study of the Safety and Immunogenicity of ChAd63 RH5 and MVA RH5 Given Intramuscularly at 0 and 2-months in Healthy Adults, Children and Infants in Tanzania

NCT03435874 is registered in ClinicalTrials.gov with University of Oxford as lead sponsor.

NCT NCT03435874
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03435874 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Age De-escalation Dose-escalation Randomised, Double-blind, Controlled Study of the Safety and Immunogenicity of ChAd63 RH5 and MVA RH5 Given Intramuscularly at 0 and 2-months in Healthy Adults, Children and Infants in Tanzania
Lead sponsor
University of Oxford
Phase
Phase 1
Overall status
Completed
Start date
April 12, 2018
Completion date
July 11, 2019
Enrollment
63 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria,falciparum